Alternating drug combo for triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This phase 2 trial tests two different drug combinations given in an alternating pattern for people with advanced triple-negative breast cancer that is HER2-low. The goal is to see if this approach is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic or locally advanced breast cancer that is triple-negative and HER2-low.
- You are at least 18 years old.
- You are in fairly good health (ECOG score 0 or 1).
- Your heart, kidney, liver, and blood cell levels are within acceptable ranges.
- You have not previously received certain antibody-drug conjugates targeting HER2 or TROP2.
- You agree to use effective birth control during the study and for several months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two investigational drugs—sacituzumab govitecan and a CDK7 inhibitor—in people with advanced triple-negative breast cancer who have already tried several treatments. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a combination of two drugs—sacituzumab govitecan and toripalimab—against another combination (toripalimab plus nab-paclitaxel) for people with advanced triple-negative breast cancer that is PD-L1 positive. The goal is to see which combination works better and has fewer side effects.
This trial tests a cancer antibody-drug combination plus pembrolizumab (immunotherapy) versus standard treatment. It’s for people with triple-negative breast cancer that still has invasive disease in the breast or lymph nodes after surgery and chemotherapy before surgery.
This trial tests a combination of two drugs, naxitamab and sacituzumab govitecan, for people with metastatic triple-negative breast cancer that has already been treated with at least one chemotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a two-drug combination (sacituzumab govitecan and pembrolizumab) versus sacituzumab govitecan alone before surgery for low-risk, triple-negative breast cancer that hasn't spread. The goal is to see which approach works better at shrinking tumors.
This trial studies how well sacituzumab govitecan (a targeted cancer drug) works for metastatic breast cancer that is HER2-negative. The study focuses on real-world patient experiences and quality of life in Chinese patients.
Hear when a new Neoplasm Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.